Management tracks: GSK, Orphazyme, Kymera and more
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) declined to confirm news reports stating it will appoint Jonathan Symonds as chairman to succeed Philip Hampton, who has served in the role since 2015. The Financial Times and Bloomberg, citing undisclosed sources, said the appointment still requires approval from banking regulators. Symonds is deputy group chairman at HSBC and has served as CFO at AstraZeneca plc (LSE:AZN; NYSE:AZN) and Novartis AG (NYSE:NVS; SIX:NOVN). GSK said in January Hampton would step down ahead of the planned split of its consumer healthcare and innovative R&D businesses.
Protein misfolding company Orphazyme A/S (CSE:ORPHA) hired former Shire plc and Novartis AG (NYSE:NVS; SIX:NOVN) executive Kim Stratton as CEO, effective Oct. 1. She will succeed Anders Hinsby, who is resigning. Stratton was head international commercial for Shire's specialty and rare disease portfolio and spent almost 15 years in senior management roles at Novartis. ...